drugset / Trial / NCT04161053

Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

NCT04161053

Phase 3 Recruiting 60 enrolled Tanta University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.

Timeline

Start
2018-11-01
Primary completion
2028-11
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitazoxanide Other / unclassified 500 mg
Comparator Rifaximin Other / unclassified 550 mg